Importantly, we could rule out secondary effects of the immunotherapy on IκBζ expression, as most melanoma patients exhibited similar levels of IκBζ pre- and post-immunotherapy (Supplementary Fig. S5c). The gene discussed is NFKBIZ; the disease is melanoma.